Trust but Verify: Lessons Learned for the Application of AI to Case-Based Clinical Decision-Making From Postmarketing Drug Safety Assessment at the US Food and Drug Administration

被引:0
|
作者
Ball, Robert [1 ]
Talal, Andrew H. [2 ]
Dang, Oanh [1 ]
Munoz, Monica [1 ]
Markatou, Marianthi [3 ]
机构
[1] US FDA, Off Surveillance & Epidemiol, Ctr Drug Evaluat & Res, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA
[2] Jacobs Sch Med & Biomed Sci, Buffalo, NY USA
[3] Univ Buffalo, Sch Publ Hlth & Hlth Profess, Buffalo, NY 14260 USA
关键词
drug safety; artificial intelligence; machine learning; natural language processing; causal inference; case-based reasoning; clinical decision support; TEXT MINING SYSTEM; CAUSALITY ASSESSMENT; ADVERSE; CLASSIFICATION;
D O I
10.2196/50274
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Adverse drug reactions are a common cause of morbidity in health care. The US Food and Drug Administration (FDA) evaluates individual case safety reports of adverse events (AEs) after submission to the FDA Adverse Event Reporting System as part of its surveillance activities. Over the past decade, the FDA has explored the application of artificial intelligence (AI) to evaluate these reports to improve the efficiency and scientific rigor of the process. However, a gap remains between AI algorithm development and deployment. This viewpoint aims to describe the lessons learned from our experience and research needed to address both general issues in case-based reasoning using AI and specific needs for individual case safety report assessment. Beginning with the recognition that the trustworthiness of the AI algorithm is the main determinant of its acceptance by human experts, we apply the Diffusion of Innovations theory to help explain why certain algorithms for evaluating AEs at the FDA were accepted by safety reviewers and others were not. This analysis reveals that the process by which clinicians decide from case reports whether a drug is likely to cause an AE is not well defined beyond general principles. This makes the development of high performing, transparent, and explainable AI algorithms challenging, leading to a lack of trust by the safety reviewers. Even accounting for the introduction of large language models, the pharmacovigilance community needs an improved understanding of causal inference and of the cognitive framework for determining the causal relationship between a drug and an AE. We describe specific future research directions that underpin facilitating implementation and trust in AI for drug safety applications, including improved methods for measuring and controlling of algorithmic uncertainty, computational reproducibility, and clear articulation of a cognitive framework for causal inference in case-based reasoning.
引用
收藏
页数:14
相关论文
共 16 条
  • [11] Lessons Learned From a Direct Data Entry Phase 2 Clinical Trial Under a US Investigational New Drug Application
    Jules T. Mitchel
    Judith M. Schloss Markowitz
    Hua (Helen) Yin
    Dean Gittleman
    Timothy Cho
    Yong Joong Kim
    Joonhyuk Choi
    Mitchell D. Efros
    Kerri Weingard
    Vadim Tantsyura
    Dario Carrara
    Drug information journal : DIJ / Drug Information Association, 2012, 46 : 464 - 471
  • [12] Lessons Learned From a Direct Data Entry Phase 2 Clinical Trial Under a US Investigational New Drug Application
    Mitchel, Jules T.
    Markowitz, Judith M. Schloss
    Yin, Hua
    Gittleman, Dean
    Cho, Timothy
    Kim, Yong Joong
    Choi, Joonhyuk
    Efros, Mitchell D.
    Weingard, Kerri
    Tantsyura, Vadim
    Carrara, Dario
    DRUG INFORMATION JOURNAL, 2012, 46 (04): : 464 - 471
  • [13] Transparency in European Medicines Agency and US Food and Drug Administration Decision Making: Is It Possible to Identify the Rationale for Divergences in Approved Indication From Public Assessment Reports?
    Bujar, Magda
    Ferragu, Sara
    McAuslane, Neil
    Liberti, Lawrence
    Kuhler, Thomas C.
    CLINICAL THERAPEUTICS, 2021, 43 (05) : 888 - 905
  • [14] Evaluation of AI-generated responses by different artificial intelligence chatbots to the clinical decision-making case-based questions in oral and maxillofacial surgery
    Azadi, Ali
    Gorjinejad, Fatemeh
    Mohammad-Rahimi, Hossein
    Tabrizi, Reza
    Alam, Mostafa
    Golkar, Mohsen
    ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY, 2024, 137 (06): : 587 - 593
  • [15] Physiologically Based Pharmacokinetic Modeling in Regulatory Science: An Update From the US Food and Drug Administration's Office of Clinical Pharmacology
    Grimstein, Manuela
    Yang, Yuching
    Zhang, Xinyuan
    Grillo, Joseph
    Huang, Shiew-Mei
    Zineh, Issam
    Wang, Yaning
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 108 (01) : 21 - 25
  • [16] Applying Decision Analysis to Inform the US Food and Drug Administration's Benefit-Risk Assessment of Ticagrelor for Primary Prevention of Myocardial Infarction or Stroke Based on THEMIS
    Lackey, Leila G.
    Garnett, Christine E.
    Senatore, Fred
    CIRCULATION, 2021, 144 (08) : 655 - 658